Barriers to Quadruple Therapy for Veterans with HFrEF: New Data Reveals Gaps in Care

For patients diagnosed with heart failure with reduced ejection fraction (HFrEF), the goal of treatment is to rapidly implement “quadruple therapy”—a combination of four specific medication classes known to improve survival and reduce morbidity. However, a recent analysis of data from the Veterans Health Administration (VA) reveals a concerning gap: fewer than one-quarter of eligible veterans are receiving this comprehensive care.

Understanding Quadruple GDMT

Guideline-directed medical therapy (GDMT) refers to the evidence-based medications recommended for heart failure management. Quadruple therapy specifically involves the concurrent employ of these four pillars:

• Beta-blockers
• Renin-angiotensin system inhibitors (such as angiotensin receptor-neprilysin inhibitors, or ARNIs)
• Mineralocorticoid receptor antagonists (MRAs)
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors

Rapid initiation of these four classes is critical for improving patient outcomes, yet the transition from diagnosis to full therapy remains slow for many.

The Reality of Care in the VA System

A retrospective cohort study involving 52,850 patients with incident HFrEF between 2020 and 2023 found that only 21.2% of veterans without clinical contraindications achieved quadruple therapy over a median follow-up of 2.9 years. This indicates that a vast majority of eligible patients are not receiving the full spectrum of recommended care, even within a streamlined healthcare system like the VA.

Key Barriers to Treatment Adherence

While it is often assumed that medication co-pays are not a significant hurdle within the VA, the data suggests otherwise. Researchers found that even a small medication co-pay is associated with an 8% lower adjusted rate of achieving quadruple therapy. Beyond cost, other systemic and clinical hurdles include:

• Fragmented Healthcare: Lack of coordination in care delivery can delay the titration of medications.
• Transient Contraindications: Temporary medical issues may prevent the immediate start of certain drugs.
• Clinician Knowledge: Limited awareness or application of the most current guidelines can slow the implementation of all four pillars.

Disparities in Access

The study highlighted significant disparities based on ethnicity. Compared to white patients, those who identified as Black, Hispanic, or other ethnicities were less likely to be on GDMT. Interestingly, the data showed no significant differences in therapy adherence based on sex.

The “Slow-Start” Approach

A common clinical practice involves initiating only one or two GDMT pillars immediately following an HFrEF diagnosis and deferring further adjustments until a follow-up appointment, typically occurring in two to four months. This cautious approach may inadvertently extend the time-to-quadruple therapy (TTQ), delaying the full therapeutic benefit for the patient.

Key Takeaways

• Low Adoption: Only 21.2% of eligible VA patients with HFrEF achieved quadruple therapy.
• Cost Matters: Small co-pays significantly impact the likelihood of a patient receiving all four medications.
• Equity Gaps: Black and Hispanic veterans face higher barriers to receiving recommended GDMT.
• Require for Speed: Moving away from deferred follow-up adjustments toward rapid initiation is essential for improving mortality and morbidity.

Frequently Asked Questions

What is the “index date” in these studies?

In the VA study, the index date was defined as the later of the diagnosis (via ICD-10 codes) or the date the patient was recorded as having an ejection fraction (EF) ≤40%.

Why is rapid initiation of quadruple therapy critical?

Rapidly starting all four pillars of GDMT is associated with improved morbidity and mortality rates for patients newly diagnosed with HFrEF.

Are there any contraindications to this therapy?

Yes, the study specifically focused on patients with no clinical contraindications to ensure the results reflected systemic barriers rather than medical impossibilities.